Cited by 1,394Antiplatelet Therapy and Cardiovascular DiseasesInflammatory mediators and NSAID effectsPlatelet Disorders and Treatments

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin

Open access

Catella-Lawson, Francesca, Reilly, Muredach P., Kapoor, Shiv C., Cucchiara, Andrew J., DeMarco, Susan, Tournier, Barbara, Vyas, Sachin N., FitzGerald, Garret A.·2001·New England Journal of Medicine

DOI 10.1056/nejmoa003199

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Patients with arthritis and vascular disease may receive both low-dose aspirin and other nonsteroidal antiinflammatory drugs. We therefore investigated potential interactions between aspirin and commonly prescribed arthritis therapies METHODS: We administered the following combinations of drugs for six days: aspirin (81 mg every morning) two hours before ibuprofen (400 mg every morning) and the same medications in the reverse order; aspirin two hours before acetaminophen (1000 mg every morning) and the same medications in the reverse order; aspirin two hours before the cyclooxygenase-2 inhibitor rofecoxib (25 mg every morning) and the same medications in the reverse order; enteric-coated aspirin two hours before ibuprofen (400 mg three times a day); and enteric-coated aspirin two hours before delayed-release diclofenac (75 mg twice daily) RESULTS: Serum thromboxane B(2) levels (an index of cyclooxygenase-1 activity in platelets) and platelet aggregation were maximally inhibited 24 hours after the administration of aspirin on day 6 in the subjects who took aspirin before a single daily dose of any other drug, as well as in those who took rofecoxib or acetaminophen before taking aspirin. In contrast, inhibition of serum thromboxane B(2) formation and platelet aggregation by aspirin was blocked when a single daily dose of ibuprofen was given before aspirin, as well as when multiple daily doses of ibuprofen were given. The concomitant administration of rofecoxib, acetaminophen, or diclofenac did not affect the pharmacodynamics of aspirin CONCLUSIONS: The concomitant administration of ibuprofen but not rofecoxib, acetaminophen, or diclofenac antagonizes the irreversible platelet inhibition induced by aspirin. Treatment with ibuprofen in patients with increased cardiovascular risk may limit the cardioprotective effects of aspirin.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa003199

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Bombardier, C., Laine, L., Reicin, A. S., Shapiro, D., Burgos‐Vargas, R., Davis, B. R., Day, R. O., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,014
Final Report on the Aspirin Component of the Ongoing Physicians' Health Study
Steering Committee of the Physicians' Health Study Research Group (1989) · New England Journal of Medicine · doi:10.1056/nejm198907203210301 · Cited by 2,267
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,572
Self-citation
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S. C., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,304
Self-citation
The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
Picot, D., Loll, P. J., & Garavito, R. M. (1994) · Nature · doi:10.1038/367243a0 · Cited by 1,270
Platelet-Active Drugs
Patrono, C., Coller, B. S., Dalen, J. E., Gerald, G. A. F., Fuster, V., Gent, M., Hirsh, J., & Roth, G. J. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.39s · Cited by 961
Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy Subjects
Patrignani, P., Filabozzi, P., & Patrono, C. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110576 · Cited by 931
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11475-1 · Cited by 829
Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
Luong, C., Miller, A. B., Barnett, J. W., Chow, J., Ramesha, C. S., & Browner, M. F. (1996) · Nature Structural Biology · doi:10.1038/nsb1196-927 · Cited by 620
Effects of Specific Inhibition of Cyclooxygenase-2 on Sodium Balance, Hemodynamics, and Vasoactive Eicosanoids
Catella-Lawson, F., McAdam, B. F., Morrison, B. W., Kapoor, S. C., Kujubu, D. A., Antes, L. M., Lasseter, K. C., Quan, H., Gertz, B. J., & FitzGerald, G. A. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38195-9 · Cited by 596
Self-citation

Show all 44 references

Research works printed but not linked: 7

Singh G, 1999, J Rheumatol, 26, 18
Patrignani P, 1999, J Physiol Pharmacol, 50, 661
Pathmakanthan S, 1998, Ir Med J, 91, 58
Patrignani P, 1994, J Pharmacol Exp Ther, 271, 1705
Sciulli MG, Patrignani P, Seta F, et al. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells in vitro. In: Proceedings of the 11th International Conference on Advances in Prostaglandin and Leukotriene Research: Basic Science and New Clinical Applications, Florence, Italy, June 4–8, 2000:38. abstract.
Reilly IAG, 1987, Blood, 69, 180, 10.1182/blood.V69.1.180.180 · DOI
Catella-Lawson F, 1999, J Pharmacol Exp Ther, 289, 735

Sorted by citations

Items 301–400 of 1,000

Is severe epistaxis associated with acetylsalicylic acid intake?
Soyka, M., Rufibach, K., Huber, A. M., & Holzmann, D. (2009) · The Laryngoscope · doi:10.1002/lary.20695 · Cited by 58
Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction
Chang, P., Chen, Y.-J., Chang, F., Lu, J. X., Huang, W.-H., Yang, T.-C., Lee, Y., Chang, S., Lu, S., & Chen, C. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt062 · Cited by 59
Ibuprofen: Pharmacology, Therapeutics and Side Effects
Rainsford, K. D. (2012) · Springer eBooks · doi:10.1007/978-3-0348-0496-7 · Cited by 63
Nonsteroidal anti-inflammatory drugs and cardiovascular safety – translating pharmacological data into clinical readouts
Tacconelli, S., Bruno, A., Grande, R., Ballerini, P., & Patrignani, P. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1338272 · Cited by 62
Acquired Disorders of Platelet Function
Hassan, A. A., & Kroll, M. H. (2005) · Hematology · doi:10.1182/asheducation-2005.1.403 · Cited by 59
Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis
Hohlfeld, T., Zimmermann, N., Weber, A.-A., Jessen, G., Weber, H., Schrör, K., Höltje, H. D., & Ebel, R. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02800.x · Cited by 59
Nonsteroidal anti‐inflammatory drugs
Zell, J. A., Ziogas, A., Bernstein, L., Clarke, C. A., Deapen, D., Largent, J. A., Neuhausen, S. L., Stram, D. O., Ursin, G., & Anton‐Culver, H. (2009) · Cancer · doi:10.1002/cncr.24705 · Cited by 57
Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update
Moore, N. D. (2020) · Drug Safety · doi:10.1007/s40264-019-00900-8 · Cited by 65
Structural modification of aspirin to design a new potential cyclooxygenase (COX-2) inhibitors
Uzzaman, M., & Mahmud, T. (2020) · In Silico Pharmacology · doi:10.1007/s40203-020-0053-0 · Cited by 59
Cyclo-Oxygenase-2 Inhibitors
Savage, R. L. (2005) · Drugs & Aging · doi:10.2165/00002512-200522030-00001 · Cited by 58
Adverse drug interactions in dentistry
Hersh, E. V., & Moore, P. A. (2008) · Periodontology 2000 · doi:10.1111/j.1600-0757.2008.00224.x · Cited by 58
Adverse Drug Interactions
Becker, D. E. (2011) · Anesthesia Progress · doi:10.2344/0003-3006-58.1.31 · Cited by 57
Acetaminophen inhibits prostanoid synthesis by scavenging the PGHS‐activator peroxynitrite
Schildknecht, S., Daiber, A., Ghisla, S., Cohen, R. A., & Bachschmid, M. M. (2008) · The FASEB Journal · doi:10.1096/fj.06-8015com · Cited by 57
Fifty years with aspirin and platelets
Patrono, C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15966 · Cited by 58
Insights into the binding of the drugs diclofenac sodium and cefotaxime sodium to serum albumin: Calorimetry and spectroscopy
Sharma, R., Choudhary, S., & Kishore, N. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.03.007 · Cited by 56
Platelet Function Profiles in Patients with Diabetes Mellitus
Rollini, F., Franchi, F., Muñiz‐Lozano, A., & Angiolillo, D. J. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9449-0 · Cited by 56
Aspirin and coronary artery disease
Fitzgerald, D. J., & Maree, A. O. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-02-0127 · Cited by 56
Herb–Drug Interaction in Inflammatory Diseases: Review of Phytomedicine and Herbal Supplements
Lippert, A., & Renner, B. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061567 · Cited by 61
Risk of stroke associated with nonsteroidal anti-inflammatory drugs
Bavry, A. A., & Park, K. E. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s54159 · Cited by 60
Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.
Fries, J. F., & Bruce, B. (2003) · PubMed · Cited by 55
Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease
Title, L. M., Giddens, K., McInerney, M. M., McQueen, M., & Nassar, B. A. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.05.006 · Cited by 55
Mechanism of Hypercholesterolemia-Induced Atherosclerosis
Prasad, K., & Mishra, M. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2306212 · Cited by 65
Drug Insight: cyclo-oxygenase-2 inhibitors—a critical appraisal
Hinz, B., Renner, B., & Brune, K. (2007) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0619 · Cited by 53
The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary
Bell, A., Roussin, A., Cartier, R., Chan, W., Douketis, J. D., Gupta, A. K., Kraw, M. E., Lindsay, T. F., Love, M. P., Pannu, N., et al. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.12.033 · Cited by 54
Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals
Fosbøl, E. L., Køber, L., Torp-Pedersen, C. T., & Gislason, G. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.501331 · Cited by 54
Acetaminophen, like conventional NSAIDs, may reduce synovitis in osteoarthritic knees
Brandt, K. D., Mazzuca, S. A., & Buckwalter, K. A. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kel100 · Cited by 54
Safety of Nonsteroidal Antiinflammatory Drugs in Patients with Cardiovascular Disease
Danelich, I. M., Wright, S. S., Lose, J. M., Tefft, B. J., Cicci, J. D., & Reed, B. N. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1584 · Cited by 58
Risk of ischemic stroke associated with non‐steroidal anti‐inflammatory drugs and paracetamol: a population‐based case‐control study
García-Poza, P., de Abajo, F. J., Gil, M., Chacón, A., Bryant, V., & García‐Rodríguez, L. A. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12855 · Cited by 54
Cyclooxygenase‐2 inhibitors: promise or peril?
Mengle-Gaw, L. J., & Schwartz, B. D. (2002) · Mediators of Inflammation · doi:10.1080/09629350290000041 · Cited by 52
NSAIDs, Risks, and Gastroprotective Strategies: Current Status and Future
Graham, D. Y., & Chan, F. K. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.007 · Cited by 53
Accelerated atherosclerosis in inflammatory rheumatic diseases
Haskard, D. O. (2004) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740410010281 · Cited by 53
Antiplatelet drug nonresponsiveness
Gladding, P. A., Webster, M. W. I., Ormiston, J., Olsen, S., & White, H. D. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.12.034 · Cited by 53
An update on K awasaki disease II : Clinical features, diagnosis, treatment and outcomes
Yim, D., Curtis, N. C., Cheung, M. M. H., & Burgner, D. P. (2013) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.12221 · Cited by 52
COX‐2 inhibitors selectively block prostacyclin synthesis in endotoxin exposed vascular smooth muscle cells
Schildknecht, S., Bachschmid, M. M., Baumann, A., & Ullrich, V. (2004) · The FASEB Journal · doi:10.1096/fj.03-0609fje · Cited by 52
Antiplatelet drug interactions
Mackenzie, I. S., Coughtrie, M. W. H., MacDonald, T. M., & Wei, L. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02299.x · Cited by 51
Short-term use of nonsteroidal anti-inflammatory drugs and adverse effects
Aminoshariae, A., Kulild, J., & Donaldson, M. (2015) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2015.07.020 · Cited by 51
Aspirin: A History, A Love Story
Wick, J. Y. (2012) · The Consultant Pharmacist · doi:10.4140/tcp.n.2012.322 · Cited by 51
How I use laboratory monitoring of antiplatelet therapy
Michelson, A. D., & Bhatt, D. L. (2017) · Blood · doi:10.1182/blood-2017-03-742338 · Cited by 53
Contribution of cyclooxygenase-1 to thromboxane formation, platelet–vessel wall interactions and atherosclerosis in the ApoE null mouse
McClelland, S., Gawaz, M., Kennerknecht, E., Konrad, C. S. I., Sauer, S., Schürzinger, K., Maßberg, S., Fitzgerald, D. J., & Belton, O. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.04.016 · Cited by 50
Meloxicam Does Not Affect the Antiplatelet Effect of Aspirin in Healthy Male and Female Volunteers
van Ryn, J., Kink‐Eiband, M., Kuritsch, I., Feifel, U., Hanft, G., Wallenstein, G., Trummlitz, G., & Pairet, M. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004266623 · Cited by 50
Relationship between Vitamin D Binding Protein and Aspirin Resistance in Coronary Ischemic Patients: A Proteomic Study
López-Farré, A. J., Mateos‐Cáceres, P. J., Sacristán, D., Azcona, L. J., Bernardo, E., de Prada, T. P., Alonso‐Orgaz, S., Fernández‐Arquero, M., Fernández‐Ortíz, A., & Macaya, C. (2007) · Journal of Proteome Research · doi:10.1021/pr060600i · Cited by 50
Selecting Nonprescription Analgesics
Peterson, G. M. (2005) · American Journal of Therapeutics · doi:10.1097/00045391-200501000-00010 · Cited by 50
Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy
Schlansky, B. L., & Hwang, J. H. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-008-2275-5 · Cited by 51
Nonsteroidal Anti-inflammatory Drug Treatment for Postoperative Pericardial Effusion
Meurin, P., Tabet, J., Thabut, G., Cristofini, P., Farrokhi, T., Fischbach, M., Pierre, B., Driss, A. B., Renaud, N., Iliou, M. C., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-3-201002020-00004 · Cited by 50
Comparison of postoperative complications after total hip arthroplasty among patients receiving aspirin, enoxaparin, warfarin, and factor Xa inhibitors
Agaba, P., Kildow, B. J., Dhotar, H. S., Seyler, T. M., & Bolognesi, M. P. (2017) · Journal of Orthopaedics · doi:10.1016/j.jor.2017.08.002 · Cited by 52
Cyclooxygenase-2 and atherosclerosis
Linton, M. F., & Fazio, S. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200210000-00005 · Cited by 50
Optimal Duration of Antiplatelet Therapy in Recipients of Coronary Drug-Eluting Stents
Zimarino, M., Renda, G., & Caterina, R. D. (2005) · Drugs · doi:10.2165/00003495-200565060-00001 · Cited by 50
Manganese-mefenamic acid complexes exhibit high lipoxygenase inhibitory activity
Feng, J., Du, X., Liu, H., Sui, X., Zhang, C., Tang, Y., & Zhang, J. (2014) · Dalton Transactions · doi:10.1039/c4dt01111b · Cited by 49
Involvement of COX-1 in A3 adenosine receptor-mediated contraction through endothelium in mice aorta
Ansari, H. R., Nadeem, A., Tilley, S. L., & Mustafa, S. J. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00764.2007 · Cited by 49
Antipyretic Analgesics: Nonsteroidal Antiinflammatory Drugs, Selective COX-2 Inhibitors, Paracetamol and Pyrazolinones
Hinz, B., & Brune, K. (2007) · Springer eBooks · doi:10.1007/978-3-540-33823-9_3 · Cited by 50
The impact of low‐dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non‐selective non‐steroidal anti‐inflammatory drug or a cyclo‐oxygenase‐2‐selective inhibitor
Goldstein, J. L., Lowry, S., Lanza, F. L., Schwartz, H. I., & Dodge, W. E. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02912.x · Cited by 50
Aspirin and Clopidogrel Resistance
Fitzgerald, D. J., & Maree, A. O. (2007) · Hematology · doi:10.1182/asheducation-2007.1.114 · Cited by 49
Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion
van den Oever, I. A., van Sijl, A. M., & Nurmohamed, M. T. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x13491025 · Cited by 48
Topical nonsteroidal anti-inflammatory drugs for the treatment of pain due to soft tissue injury: diclofenac epolamine topical patch
Lionberger (2010) · Journal of Pain Research · doi:10.2147/jpr.s13238 · Cited by 48
OTC analgesics and drug interactions: clinical implications
Fendrick, A. M., Pan, D. E., & Johnson, G. E. (2008) · Osteopathic Medicine and Primary Care · doi:10.1186/1750-4732-2-2 · Cited by 47
Anti-inflammatory and immunosuppressant drugs
Rang, H. P., Dale, M. M., Ritter, J., & Flower, R. J. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-06911-6.50019-0 · Cited by 48
Eicosanoids and the Vascular Endothelium
Egan, K. M., & FitzGerald, G. A. (2006) · Springer eBooks · doi:10.1007/3-540-32967-6_6 · Cited by 52
Self-citation
Suppression of Oxidative Stress as a Mechanism of Reduction of Hypercholesterolemic Atherosclerosis by Aspirin
Prasad, K., & Lee, P. (2003) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840300800i109 · Cited by 48
Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice
Fiorucci, S., Mencarelli, A., Cipriani, S., Renga, B., Palladino, G., Santucci, L., & Distrutti, E. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01481.x · Cited by 47
Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
van Staa, T. P., Rietbrock, S., Setakis, E., & Leufkens, H. G. M. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01991.x · Cited by 47
Aspirin Resistance
Fehér, G., Koltai, K., Papp, E., Alkonyi, B., Sólyom, A., Kenyeres, P., Késmárky, G., Czopf, L., & Tóth, K. (2006) · Drugs & Aging · doi:10.2165/00002512-200623070-00002 · Cited by 47
Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs
Patrono, C. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0702-4 · Cited by 47
Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy Subjects
Schwartz, J. I., Dallob, A. L., Larson, P., Laterza, O., Miller, J., Royalty, J. E., Snyder, K., Chappell, D. L., Hilliard, D. A., Flynn, M., et al. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008317590 · Cited by 47
Coagulation Management in Pediatric Mechanical Circulatory Support
Drews, T., Stiller, B., Hübler, M., Weng, Y., Berger, F. F., & Hetzer, R. (2007) · ASAIO Journal · doi:10.1097/mat.0b013e3181492929 · Cited by 47
EIDOS
Ferner, R. E., & Aronson, J. K. (2009) · Drug Safety · doi:10.2165/11318910-000000000-00000 · Cited by 47
Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study
Rahme, E., Bardou, M., Dasgupta, K., Toubouti, Y. M., Ghosn, J., & Barkun, A. N. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kel223 · Cited by 47
Aspirin resistance
Tran, H. A., Anand, S. S., Hankey, G. J., & Eikelboom, J. W. (2007) · Thrombosis Research · doi:10.1016/j.thromres.2006.08.014 · Cited by 47
Cardiovascular Risks of Cyclooxygenase-2 Inhibitors: Where We Stand Now
Finckh, A., & Aronson, M. D. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-3-200502010-00013 · Cited by 47
Acetaminophen, Nonsteroidal Anti-Inflammatory Drugs, and Hypertension
Spence, J. D., Großer, T., & FitzGerald, G. A. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19315 · Cited by 49
Self-citation
Pyridine and pyrimidine analogs of acetaminophen as inhibitors of lipid peroxidation and cyclooxygenase and lipoxygenase catalysis
Nam, T. G., Nara, S. J., Zagol-Ikapitte, I. A., Cooper, T. B., Valgimigli, L., Oates, J. A., Porter, N. A., Boutaud, O. G., & Pratt, D. A. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b912528k · Cited by 46
Herbal, Prescribed, and Over-the-Counter Drug Use in Older Women: Prevalence of Drug Interactions
Yoon, S. L., & Schaffer, S. D. (2006) · Geriatric Nursing · doi:10.1016/j.gerinurse.2006.02.014 · Cited by 46
COX-2 in play at the AHA and the FDA
FitzGerald, G. A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.05.007 · Cited by 46
Self-citation
The Cardiovascular Pharmacology of COX-2 Inhibition
Fries, S., & Großer, T. (2005) · Hematology · doi:10.1182/asheducation-2005.1.445 · Cited by 45
An evidence‐based update of the use of analgesics in dentistry
Ong, C. K. S., & Seymour, R. A. (2008) · Periodontology 2000 · doi:10.1111/j.1600-0757.2008.00225.x · Cited by 46
The Clinical Diagnosis and Management of Kawasaki Disease: a Review and Update
Zhu, F. H., & Ang, J. Y. (2016) · Current Infectious Disease Reports · doi:10.1007/s11908-016-0538-5 · Cited by 46
Renal Cyclooxygenase-2 (Cox-2)
Krämer, B. K., Kammerl, M., & Kömhoff, M. (2004) · Kidney & Blood Pressure Research · doi:10.1159/000075811 · Cited by 46
Antiplatelet Drug Resistance and Drug-Drug Interactions: Role of Cytochrome P450 3A4
Lau, W. C., & Gurbel, P. A. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9084-4 · Cited by 46
Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis
Goodson, N. J., Silman, A. J., Pattison, D. J., Lunt, M., Bunn, D. K., Luben, R., Day, N., Khaw, K., & Symmons, D. P. M. (2004) · Lara D. Veeken · doi:10.1093/rheumatology/keh161 · Cited by 46
Population Pharmacodynamic Modelling of Aspirin- and Ibuprofen-Induced Inhibition of Platelet Aggregation in Healthy Subjects
Hong, Y., Gengo, F. M., Rainka, M. M., Bates, V. E., & Mager, D. E. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847020-00006 · Cited by 46
Migraine and cardiovascular disease in women and the role of aspirin: Subgroup analyses in the Women’s Health Study
Kurth, T., Diener, H., & Buring, J. E. (2011) · Cephalalgia · doi:10.1177/0333102411412628 · Cited by 46
Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology
Schmidt, M., Lamberts, M., Olsen, A. S., Fosbøl, E. L., Niessner, A., Tamargo, J. L., Rosano, G. M. C., Agewall, S., Kaski, J. C., Kjeldsen, K. P., et al. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv054 · Cited by 46
Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST
de Cardiología, G. D. T. P. E. D. Y. T. D. S. C. A. S. E. D. S. S. D. L. S. E. (2007) · Revista Española de Cardiología · doi:10.1157/13111518 · Cited by 46
Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs
Bolten, W. W. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.036269 · Cited by 47
Aspirin resistance in stroke: 2004
Sztriha, L., Sas, K., & Vécsei, L. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.11.023 · Cited by 45
Aspirin resistance: Truth or dare
Lordkipanidzé, M., Pharand, C., Palisaitis, D., & Diodati, J. G. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.05.011 · Cited by 44
Piperlongumine, a constituent of Piper longum L., inhibits rabbit platelet aggregation as a thromboxane A2 receptor antagonist
Iwashita, M., Oka, N., Ohkubo, S., Saito, M., & Nakahata, N. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.05.073 · Cited by 44
Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence
Kolandaivelu, K., & Bhatt, D. L. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.71 · Cited by 44
Historical Lessons in Translational Medicine
Fitzgerald, D. J., & FitzGerald, G. A. (2013) · Circulation Research · doi:10.1161/circresaha.111.300271 · Cited by 46
Self-citation
Efficacy of celecoxib versus ibuprofen for the treatment of patients with osteoarthritis of the knee: A randomized double-blind, non-inferiority trial
Gordo, A. C., Walker, C., Armada, B., & Zhou, D. (2017) · Journal of International Medical Research · doi:10.1177/0300060516673707 · Cited by 44
Application of HPLC for the Simultaneous Determination of Aceclofenac, Paracetamol and Tramadol Hydrochloride in Pharmaceutical Dosage Form
Chandra, P. (2012) · Scientia Pharmaceutica · doi:10.3797/scipharm.1108-04 · Cited by 44
Paradoxical Rebound Platelet Activation After Painkillers Cessation: Missing Risk for Vascular Events?
Serebruany, V. L., Malinin, A. I., & Bhatt, D. L. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.11.007 · Cited by 44
Estrategia clínica para la prevención de los efectos adversos sobre el tracto digestivo de los antiinflamatorios no esteroideos
Lanas, Á., Martín-Mola, E., Ponce, J., Navarro, F., Piqué, J., & Blanco, F. J. (2003) · Gastroenterología y Hepatología · doi:10.1016/s0210-5705(03)70400-2 · Cited by 44
Osteoarthritic pain: a review of current, theoretical and emerging therapeutics
Read, S., & Dray, A. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.5.619 · Cited by 44
Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells
Sciulli, M. G., Seta, F., Tacconelli, S., Capone, M. L., Ricciotti, E., Pistritto, G., & Patrignani, P. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705078 · Cited by 44
Aspirin resistance in patients with chronic renal failure
Tanrikulu, A. M., Özben, B., Koç, M., Papila-Topal, N., Özben, T., & Caymaz, O. (2011) · Journal of Nephrology · doi:10.5301/jn.2011.6259 · Cited by 43
Overview of Aspirin and Platelet Biology
Santos‐Gallego, C. G., & Badimón, J. J. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.12.018 · Cited by 48
Development and evaluation of diclofenac sodium thermorevesible subcutaneous drug delivery system
Nasir, F., Iqbal, Z., Khan, J. A., Khan, A., Khuda, F., Ahmad, L., Khan, A., Khan, A., Dayoo, A., & Roohullah (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.10.009 · Cited by 43
Association of COX-2 rs20417 with aspirin resistance
Sharma, V., Kaul, S., Al‐Hazzani, A. A., Alshatwi, A. A., Jyothy, A., & Munshi, A. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0777-8 · Cited by 43
Resveratrol attenuates thromboxane A2 receptor agonist-induced platelet activation by reducing phospholipase C activity
Yang, Y.-M., Chen, J.-Z., Wang, X., Wang, S., Hu, H., & Wang, H. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.009 · Cited by 43
Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA1/2polymorphism
Kranzhöfer, R., & Ruef, J. (2006) · Platelets · doi:10.1080/09537100500441101 · Cited by 43

Authors: Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A.
Affiliations: University of Pennsylvania (US)
ORCID: Reilly, Muredach P.
Kapoor, Shiv C.
Cucchiara, Andrew J.
Tournier, Barbara
FitzGerald, Garret A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-12-20
Volume: 345
Issue: 25
Pages: 1809-1817
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa003199
OpenAlex: W2011327495
Cited by: 1,394
References: 44
Citations by year: 2026: 19 · 2025: 15 · 2024: 18 · 2023: 18 · 2022: 33 · 2021: 43 · 2020: 33 · 2019: 40 · 2018: 40 · 2017: 46 · 2016: 41 · 2015: 56 · 2014: 46 · 2013: 69 · 2012: 79
FWCI: 50.64
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Heart, Lung, and Blood Institute (HL 5400, HL62250, P01HL062250)
National Center for Research Resources (M01-RR-00040, M01RR000040)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords: aspirin, ibuprofen, cyclooxygenase inhibitors, rofecoxib, diclofenac, paracetamol, drug interactions, platelet aggregation, thromboxane B2, antiplatelet activity, nonsteroidal anti-inflammatory drugs, arthritis treatment, cardiovascular risk, cardioprotection
MeSH terms: Acetaminophen, Adult, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Diclofenac, Drug Interactions, Drug Therapy, Combination, Humans, Ibuprofen, Isoenzymes, Lactones, Membrane Proteins, Middle Aged, Platelet Aggregation, Platelet Aggregation Inhibitors, Prostaglandin-Endoperoxide Synthases, Sulfones, Thromboxane B2, Dinoprostone, Cyclooxygenase Inhibitors, Cross-Over Studies, Analgesics, Non-Narcotic, Cyclooxygenase 1, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks